Competition to be intensified in hepatitis B drug market

Published: 2012-09-20 07:00:00

Updated: 2012-09-20 07:00:00

Competition in the domestic hepatitis B drug market is likely to heat up because Yuhan Corp., Korea’s exclusive seller of Gilead Science Viread, are poised to occupy the runner-up slot by deploying aggressive marketing strategies of Viread, which has been recently included in the insurance list.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK